Blog post

German elections: seizing the moral and economic opportunity of global health security

The new German government should play its part in global health security and preparedness.

Publishing date
24 September 2021

This blog is part of a series by CGD and partnering institutions from Germany focused on presenting specific policy proposals for the next German government’s leadership on global development issues.

The COVID-19 pandemic has exposed the ways in which the global health architecture was unprepared for a catastrophic health emergency, and above all, the limited and late international financing that has led to widespread disease and death. New pandemic waves threaten to derail recoveries.

As we near the end of a second year of living with continually spreading and mutating COVID-19, Europe and Germany have both a moral and an economic opportunity to increase their commitment to global health even further. Germany can build on its expanding presence in the global health sphere and Global Health Strategy to deliver more equitable global access to vaccines and treatments for COVID-19, to enact fit-for-purpose financing to build surveillance systems and head off the next pandemic risk and to grow the country’s industrial strengths to produce and deliver highly efficacious vaccines to the world and reduce the likelihood of economic and supply chain disruptions in the future. A new German government also represents further opportunity for collaboration with other European Union nations on initiatives like the nascent European Health Union to detect, prepare and respond collectively to health threats. With losses from COVID-19, according to the International Monetary Fund, reaching up to half a trillion dollars every month, there is no time to waste.

With the German elections at hand, we propose a high-level five-point agenda for the next Government to enhance global health security to respond to the current COVID-19 pandemic and prepare for future biosecurity risks. And while we focus on the German government, many of the proposals can be most usefully pursued in the context of the European Union – which is not the main focus of this blog.

1. Build on a strong track record in global health security and pandemic preparedness, and Germany’s commitment to the free flow of vaccines and vaccine inputs across borders

In response to the COVID-19 pandemic, the German government expanded its focus on global health and pandemic preparedness. Germany’s new cross-ministerial global health strategy for 2020-2030, adopted by the Cabinet in October 2020, explicitly mentions pandemic prevention as a top priority and emphasises strengthening the multilateral global health architecture.

Germany has been a major financial contributor to the response to the current pandemic. Germany committed more than US$500 million to the World Health Organisation’s COVID-19 response. To assist developing countries in responding to the impacts of COVID-19, Germany contributed €10 million to the Health Emergencies Preparedness and Response Trust Fund Programme (HEPR Programme) at the World Bank. The German government was also an early funder of the Coalition for Epidemic Preparedness Innovations (CEPI), contributing an initial €140 million early on in March 2020 to accelerate the development of a COVID-19 vaccine, and providing €2.2 billion to the Access to COVID-19 Tools Accelerator (ACT-A), most of which is going to support the vaccine platform COVAX. In addition, Germany contributes via the EU financing mechanisms another roughly €1 billion. Germany is thus second in financial contributions, coming behind the US, which is estimated to have donated roughly $6.2 billion.

Germany also committed to donate 30 million doses, of which 6.6 million have been donated. The EU is committed to now donate roughly 400 million doses.

Further, the WHO and Germany in September 2021 launched a new Hub for Pandemic and Epidemic Intelligence based in Berlin, a global platform to predict, detect and respond to pandemic and epidemic risks worldwide.

Beyond aid, production of vaccines in Germany and the EU has been critical for the global supply. Notably, as of early August, firms based in Germany had produced more than 200 million vaccine doses for export, honouring purchasing contracts with 138 countries and avoiding export bans. This strategy stands in sharp contrast to the US and Indian governments’ moves towards protectionism and nationalism during the same period.

In a new or next government, Germany should continue the trajectory by pushing harder on domestic vaccination coverage while accelerating the effort, together with the rest of Team Europe, to donate more surplus vaccine doses more quickly to lower-income countries via COVAX.

Financing across the multilateral system should be sustained. In Germany, as elsewhere in the world, policy alignment and collaboration across the range of related ministries, as well as the federal states, is necessary for a coherent and high-impact approach to pandemic preparedness and response.

2. At the G20 and the G7, work with counterparts to enhance coordination and financing for pandemics to deliver greater equity in the COVID-19 response and better preparedness for the next pandemic risk

The G20 and G7 are key opportunities for both formal and informal peer pressure. Germany is well-placed to use its voice and perspectives to encourage action and commitment to these issues from its high-income country cohort.

The G20 issued the Rome Declaration in May 2021 with calls for enhanced coordination and investments in long-term pandemic preparedness, prevention, detection and response, as well as surge capacity. The G7 echoed that call in June 2021 via the Carbis Bay Communiqué, but failed to identify ways to implement its vision for pandemic preparedness and response. In July 2021, the G20 Finance Ministers and Central Bank Governors welcomed the report of the G20-mandated High-Level Independent Panel on Financing the Global Commons for Pandemic Preparedness and Response (HLIP) in which we both participated.

Now is the time for clearer actions. Germany is actively engaged in the deliberations around the report’s recommendations as part of the G20 Finance and Health Informal Group, convened in follow-up to the July meeting to take forward the HLIP’s recommendations. Germany should work with allies to drive an ambitious and effective new governance or oversight body and multilateral financing mechanism to ensure predictable global financing and effective use of those funds to meet standards for pandemic preparedness and response worldwide.

Germany’s presidency of the G7 in 2022 also represents an opportunity to push forward the commitment to pandemic preparedness and prevention and with a tangible roadmap forward for the long-term prioritisation of, and institutional arrangements for, pandemic preparedness.

3. Make financing global public goods part of the World Bank’s core mandate

Given its leading role in international development financing (#2 in OECD Official Development Assistance), Germany should push to make global public goods, especially for pandemic security, part of the core mandates of the World Bank and other multilateral development banks.

Financing global public goods can be operationalised as part of the World Bank’s Green, Resilient and Inclusive Development (GRID) approach, to make long-term, integrated, and sustained development progress. The German government, in collaboration with other countries and the World Bank, can be instrumental in advising on the institutional, operational and financial arrangements required to make those changes happen. Germany has long been a key voice for global public goods financing in the reform and renewal of the global health and development finance agencies, and supported the creation of the pilot Global Public Goods financing window at the World Bank.

At bare minimum, Germany should increase its contribution to IDA20 at the World Bank, given the COVID-19 catastrophe, while also urging World Bank management to include a cross-cutting theme on crisis preparedness in IDA20. Germany could also consider expanding access to concessional resources to create incentives for pandemic preparedness borrowing by co-financing International Development Association (IDA) operations and buying down International Bank for Reconstruction and Development terms for lending in middle-income countries for this purpose. Multilateral development banks are uniquely placed to incentivise investments in pandemic prevention and preparedness at country and regional levels, complementing their existing lending, and Germany can capitalise on those functions.

4. Maintain support for the WHO

Germany is the top funder of the WHO. Its contributions to the WHO, including assessed and voluntary, made up nearly 12% of all funding in the 2020-21 biennium (see more on Germany’s role in global health here). Germany should continue its strong commitment to ensuring that the WHO is financed adequately and predictably, and thus able to perform its necessary functions. But Germany can also leverage its crucial position as a top funder to pressure the WHO to increase transparency in its practices and to advocate for a system of institutional checks and balances that is executed properly. While the WHO’s role is critical, it is just one piece of the puzzle.

5. Grow Germany’s industrial strengths to produce, partner and deliver highly efficacious vaccines and other related products to the world

German firms are now major players in biotech, and this represents a win-win for Germany and the rest of the world. It is a significant economic opportunity for Germany but also a huge opportunity for the world. BioNTech’s new investments in production in Germany can boost not only EU but world supply of a highly efficacious vaccine and its active ingredients. Economically, the BioNTech success has also been a big net positive for Germany’s economy. While CureVac itself reported poor results on its vaccine candidate, the Peterson Institute’s Chad Bown suggests that much of that company’s supply chain could repurposed to make one of the other mRNA vaccines. Germany can lead this repurposing. There are also opportunities to expand voluntary technology transfer and partnering to assure distributed production and ever-warm manufacturing around the world. The initial €50 million investment in South Africa is a good start but much more can be done.

Global health security and preparedness also represent areas for continued cooperation within the EU, in which Germany can play a large role. In her 15 September State of the Union speech, Commission President Ursula von der Leyen doubled down on her commitment to build a European Health Union and proposed a new health preparedness and resilience mission for the whole EU, calling for an investment of €50 billion by 2027. The new German government should play its part.

Recommended citation:

Glassman, A. and G. Wolff (2021) ‘German elections: seizing the moral and economic opportunity of global health security ’, Bruegel Blog, 24 September


About the authors

  • Guntram B. Wolff

    Guntram Wolff is a Senior fellow at Bruegel. He is also a Professor of Public Policy and Economics at the Willy Brandt School of Public Policy. From 2022-2024, he was the Director and CEO of the German Council on Foreign Relations (DGAP) and from 2013-22 the director of Bruegel. Over his career, he has contributed to research on European political economy, climate policy, geoeconomics, macroeconomics and foreign affairs. His work was published in academic journals such as Nature, Science, Research Policy, Energy Policy, Climate Policy, Journal of European Public Policy, Journal of Banking and Finance. His co-authored book “The macroeconomics of decarbonization” is published in Cambridge University Press.

    An experienced public adviser, he has been testifying twice a year since 2013 to the informal European finance ministers’ and central bank governors’ ECOFIN Council meeting on a large variety of topics. He also regularly testifies to the European Parliament, the Bundestag and speaks to corporate boards. In 2020, Business Insider ranked him one of the 28 most influential “power players” in Europe. From 2012-16, he was a member of the French prime minister’s Conseil d’Analyse Economique. In 2018, then IMF managing director Christine Lagarde appointed him to the external advisory group on surveillance to review the Fund’s priorities. In 2021, he was appointed member and co-director to the G20 High level independent panel on pandemic prevention, preparedness and response under the co-chairs Tharman Shanmugaratnam, Lawrence H. Summers and Ngozi Okonjo-Iweala. From 2013-22, he was an advisor to the Mastercard Centre for Inclusive Growth. He is a member of the Bulgarian Council of Economic Analysis, the European Council on Foreign Affairs and  advisory board of Elcano.

    Guntram joined Bruegel from the European Commission, where he worked on the macroeconomics of the euro area and the reform of euro area governance. Prior to joining the Commission, he worked in the research department at the Bundesbank, which he joined after completing his PhD in economics at the University of Bonn. He also worked as an external adviser to the International Monetary Fund. He is fluent in German, English, and French. His work is regularly published and cited in leading media. 

  • Amanda Glassman

    Amanda Glassman is executive vice president and senior fellow at the Centre for Global Development and also serves as chief executive officer of CGD Europe. Her research focuses on priority-setting, resource allocation and value for money in global health, as well as data for development. Prior to her current position, she served as director for global health policy at the Centre from 2010 to 2016, and has more than 25 years of experience working on health and social protection policy and programs in Latin America and elsewhere in the developing world.

    Prior to joining CGD, Glassman was principal technical lead for health at the Inter-American Development Bank, where she led policy dialogue with member countries, designed the results-based grant program Salud Mesoamerica 2015 and served as team leader for conditional cash transfer programs such as Mexico’s Oportunidades and Colombia’s Familias en Accion. From 2005-2007, Glassman was deputy director of the Global Health Financing Initiative at Brookings and carried out policy research on aid effectiveness and domestic financing issues in the health sector in low-income countries. Before joining the Brookings Institution, Glassman designed, supervised and evaluated health and social protection loans at the Inter-American Development Bank and worked as a Population Reference Bureau Fellow at the US Agency for International Development. Glassman holds a MSc from the Harvard School of Public Health and a BA from Brown University, has published on a wide range of health and social protection finance and policy topics, and is editor and co-author of the books What's In, What's Out: Designing Benefits for Universal Health Coverage (Centre for Global Development, 2017), Millions Saved: New Cases of Proven Success in Global Health (Centre for Global Development 2016), From Few to Many: A Decade of Health Insurance Expansion in Colombia (IDB and Brookings 2010), and The Health of Women in Latin America and the Caribbean (World Bank 2001).

Related content